Chad will speak on "The 2023 Hatch-Waxman Year in Review: Pivotal Moments and Policy Shifts for Small Molecule Patents." Panelists will reflect on 2023's most important developments impacting small molecule drugs, including major court decisions; regulatory and policy changes; and industry shifts.
Matt will speak on "§112 Before the Supreme Court and Federal Circuit: Navigating Genus Claims and MPF Strategies Post Amgen and Xencor." Panelists will discuss the evolving landscape of §112 in Hatch-Waxman litigation, illustrated by the Supreme Court’s decision in Amgen v. Sanofi and the Federal Circuit’s pending decision in In re: Xencor.
Click here for more information, including how to register.